MM-120

MindMed has appointed Matt Wiley as Chief Commercial Officer to oversee the commercial strategy for MM120 ODT, a potential treatment for generalized anxiety disorder and major depressive disorder.

Mind Medicine's MM120, an optimized LSD formulation, demonstrates significant anxiety symptom reduction in Phase 2b trials for generalized anxiety disorder, advancing to Phase 3 testing.

MindMed has dosed the first patient in its Phase 2b clinical trial evaluating MM120 for the treatment of Generalized Anxiety Disorder (GAD).

MindMed's MM120, an orally disintegrating tablet form of LSD, is progressing through Phase III trials for generalized anxiety disorder (GAD) and major depressive disorder (MDD).

MindMed's MM120, a lysergide d-tartrate (LSD) formulation, demonstrates rapid and durable improvement in patients with generalized anxiety disorder (GAD) after a single dose in Phase 2b trial.